Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal products is continuously evaluated. When important safety issues arise, if applicable, we promptly notify healthcare the professionals, patients and regulatory agencies concerned in accordance with current legislation.
What is Pharmacovigilance?
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem (Ref. World Health Organization, WHO. The importance of pharmacovigilance: safety monitoring of medicinal products, Genève, WHO, 2002). In line with this general definition, the main objectives of pharmacovigilance in accordance with the applicable EU legislation are:
Pharmacovigilance is therefore an activity contributing to the protection of patient and public health.
What is an Adverse Drug Reaction?
A response to a medicinal product which is harmful and unintended (response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility).
Adverse reactions may arise from use of the product within or outside the terms of the marketing authorisation or from occupational exposure. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse, abuse and medication errors.
What is the Materiovigilance?
The Medical Device Vigilance (materiovigilance) is a system aimed at monitoring and evaluating incidents related to medical devices. The Medical Device Vigilance System aims to improve the protection of the health and safety of patients, healthcare professionals, and other users by reducing the likelihood of reoccurrence of incidents related to the use of a medical device.
What is an incident or an untoward event related to a medical device?
The term “incident” in the Medical Device Regulation (UE) 2017/745 means any malfunction or deterioration in the characteristics or performance of a device made available on the market, including use-error due to ergonomic features, as well as any inadequacy in the information supplied by the manufacturer and any undesirable side-effect.
Information on how to report an adverse drug reaction or a medical device incident
Any untoward event that occurs following medical treatment or medical device usage must be reported.
If you need to report an adverse drug reaction related to Chiesi drugs or medical device incidents on territory of Czechia, we are kindly asking you to report it to:
SÚKL (State Institute for Drug Control, Šrobárova 48, 100 41 Praha) by e-mail: farmakovigilance@sukl.cz
or directly via the web portal for the message: https://nezadouciuc.sukl.czinky/
or
Chiesi CZ s.r.o., Smrčkova 2485/4, 180 00 Praha 8 (reporting adverse reactions and / or complaints about product quality):
Tel. +420 261 211 850
Email: safety.cz@chiesi.com
